We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




7T MRI Used in Brain Disorder Research Collaboration

By LabMedica International staff writers
Posted on 16 Nov 2011
A 7-T magnetic resonance imaging (MRI) investigational scanner will be used to support academic research on functional brain mapping, high-resolution anatomic imaging of the brain, spectroscopy of the brain, assessment of tumor response to treatment, and cardiovascular imaging.

GE Healthcare (Chalfont St. More...
Giles, UK) and University of Iowa Health Care (Iowa City, USA) announced that they would collaborate on ultra-high-field MRI to study brain disorders. The purchase of the GE equipment for research use will be funded with a National Institutes of Health (NIH) high-end instrumentation grant awarded to Vincent Magnotta, PhD, in the department of radiology at University of Iowa Hospitals and Clinics in Iowa City (IA, USA).

The GE 7 T MR imaging scanner will provide ultra-high-field whole body scanning capabilities for MRI research. It will be housed in the University’s new Pappajohn Biomedical Discovery Institute, currently under construction. It is being acquired by the University of Iowa to support the research efforts of 33 funded US National Institutes of Health (NIH; Bethesda, MD, USA) investigators from five colleges (medicine, engineering, public health, liberal arts and sciences, and business) with more than 40 NIH grants. This group of researchers from University of Iowa has a wide range of interests including functional brain mapping, high-resolution anatomical imaging of the brain, spectroscopy of the brain, evaluation of tumor response to treatment, and cardiovascular imaging.

“We are honored and delighted to work with the University of Iowa to provide ultra-high-field strength MR imaging capabilities to help study patients with a variety of brain disorders,” said Jacques Coumans PhD, general manager of GE Healthcare’s MRI business. “Our 7 T MRI research system has the abilities to provide increased image resolution and sensitivity to help accelerate translational research. This collaboration is an excellent representation of how academic-industrial partnerships can help define new directions with the goal of facilitating more immediate health improvements and better outcomes.”

Three medical device vendors participated in a competitive proposal process for the research scanner purchase.

Related Links:
GE Healthcare
University of Iowa Health Care



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.